Insights
Search Results
Client Highlights
10.10.24
Wilson Sonsini Advises Cytovale on IP Matters Related to $100 Million Series D Financing
On October 10, 2024, Cytovale, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, announced that it has raised $100 million in Series D funding. The round was led by Sands Capital, with participation from new investor Canada Pension Plan Investment Board (CPP Investments), as well as existing investors Norwest Venture Partners, Global Health Investment Corporation, and Breakout Ventures. Wilson Sonsini Goodrich & Rosati advises Cytovale on intellectual property strategy generally and advised the company on IP matters related to the Series D financing. .
Cytovale’s IntelliSep test is the first and only U.S. Food and Drug Administration (FDA)-cleared cellular host diagnostic indicated for use in hospital emergency departments, where over 80 percent of sepsis cases present. The test, which takes only approximately eight minutes, provides clinicians with a first-ever look into the biology that causes sepsis, enabling care teams to quickly and confidently identify the proper diagnosis and deliver appropriate, patient-centered care. Cytovale will use the proceeds from the financing to build upon its early clinical success and accelerate commercial expansion of IntelliSep to more hospital emergency departments and health systems nationwide.
The Wilson Sonsini team that advised Cytovale on IP matters related to the financing includes Matt Bresnahan, Maysam Pessian, Nicholas Tiee, and Ben Hoar.
For more information, please see Cytovale’s news release.
Cytovale’s IntelliSep test is the first and only U.S. Food and Drug Administration (FDA)-cleared cellular host diagnostic indicated for use in hospital emergency departments, where over 80 percent of sepsis cases present. The test, which takes only approximately eight minutes, provides clinicians with a first-ever look into the biology that causes sepsis, enabling care teams to quickly and confidently identify the proper diagnosis and deliver appropriate, patient-centered care. Cytovale will use the proceeds from the financing to build upon its early clinical success and accelerate commercial expansion of IntelliSep to more hospital emergency departments and health systems nationwide.
The Wilson Sonsini team that advised Cytovale on IP matters related to the financing includes Matt Bresnahan, Maysam Pessian, Nicholas Tiee, and Ben Hoar.
For more information, please see Cytovale’s news release.
Client Highlights
5.06.24
Wilson Sonsini Advises Karius on IP Matters Related to $100 Million Series C
On May 2, 2024, Karius®, Inc. (Karius), a world leader in genomic diagnostics for infectious disease, announced the successful completion of a $100 million Series C financing. Khosla Ventures, along with new investors 5AM Ventures and Gilde Healthcare, co-led the round. New investor Seventure Partners, and existing investors Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments, Blue Water Life Sciences, Innovation Endeavors, Waycross Ventures, and others also participated. Wilson Sonsini Goodrich & Rosati advised Karius on IP matters related to the transaction.
Client Highlights
5.29.20
Firm Represents ChromaCode in $10 Million Series C Financing from Gates Foundation-Backed Adjuvant Capital
On May 19, 2020, ChromaCode, Inc., a company redefining molecular testing through data science, announced a $10 million Series C extension with an investment from Adjuvant Capital, which is backed by leading healthcare investors such as the Bill & Melinda Gates Foundation, the International Finance Corporation, and Novartis, bringing the company’s total Series C funding to $38 million. Adjuvant aims to drive meaningful improvements in the public health of low- and middle-income countries with a focus on neglected, high-burden and emerging infectious diseases, pandemic threats, and maternal and child health. Wilson Sonsini Goodrich & Rosati represented ChromaCode in the transaction.
Client Highlights
12.16.19
Firm Advises Alphamab Oncology on IP Matters Related to IPO on HKSE
On Thursday, December 12, Alphamab Oncology listed on the Main Board of The Stock Exchange of Hong Kong Limited, raising HK$1.8 billion ($230 million). Alphamab Oncology is a leading clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in biospecifics and protein engineering. Four drug candidates in the company’s pipeline have advanced to clinical development phase, including a PD-L1 antibody and two bispecific antibodies PD-L1/CTLA4 and HER2. Wilson Sonsini Goodrich & Rosati represented Alphamab Oncology on related intellectual property matters.